ArticleJournal of animal science2025
Serotonin can stimulate vasorelaxation in ovine lateral saphenous veins precontracted with ergovaline.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of serotonin and ergot alkaloids on tissue partitioning and contractile response of bovine blood vessels.Current research in toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ergot alkaloid ergovaline is a potent vasoconstrictor. Previous research has shown that ergovaline can bind serotonin (5-HT) receptors and elicit vasoconstrictive activity. Three experiments were conducted to evaluate 5-HT as a vasorelaxant in the ovine saphenous artery and vein. Blood vessels were collected from mixed-breed market ram lambs (n = 23) at slaughter. Experiment 1: artery and vein cross-sections were precontracted with 1 × 10-4 M phenylephrine in a multimyograph for 15 min, exposed to concentrations of 5-HT that ranged from 1 × 10-9 to 1 × 10-4 M for a 5-min interval. Response data were normalized to the 1 × 10-4 M phenylephrine response and were analyzed as a completely randomized design in SAS. The lateral saphenous vein (n = 5 lambs) relaxed to increasing concentrations of 5-HT (P < 0.05) with 65% to 75 % relaxation occurring at 1 × 10-7 M through 1 × 10-4 5-HT. Conversely, the lateral saphenous artery (n = 6 lambs) contracted in response to increasing concentrations of 5-HT (P < 0.05) resulting in a 255% increase from the phenylephrine response by the 1 × 10-4 M addition. Experiment 2: saphenous veins from lambs (n = 5) were exposed to increasing concentrations of selective 5-HT receptor agonists to determine the receptor subtypes involved in the previously observed vasorelaxation. Agonists for receptors 5-HT2B, 5-HT4, and 5-HT7 were used. While all three 5-HT receptor subtypes resulted in vasorelaxation (P < 0.05), the 5-HT2B agonist only stimulated a maximal relaxation of 32% compared to the agonists for 5-HT4 and 5-HT7 that resulted in maximal relaxation of 68% and 50%, respectively. Experiment 3: saphenous arteries and veins were collected from market rams (n = 7) and precontracted with 1 × 10-6 M ergovaline for 30 min. The lateral saphenous vein relaxed to increasing concentrations of 5-HT (P < 0.05) with 87 % relaxation occurring by 1 × 10-6 M 5-HT. Conversely, the lateral saphenous artery contracted in response to increasing concentrations of 5-HT (P < 0.05) resulting in a 43% increase from the ergovaline response by the 1 × 10-4 M addition. This is the first reported direct observation of stimulated relaxation of a blood vessel constricted by ergovaline. The agonist for 5-HT4 produced the greatest relaxation in the ovine lateral saphenous vein. Serotonin receptors involved in 5-HT-mediated vasorelaxation do not appear to be antagonized by ergovaline and should be targeted in subsequent research focused on mitigation of ergot alkaloid-induced vasoconstriction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.